Literature DB >> 9107160

Nonselective beta-adrenergic blockade with carvedilol does not hinder the benefits of exercise training in patients with congestive heart failure.

L Demopoulos1, M Yeh, M Gentilucci, M Testa, R Bijou, S D Katz, D Mancini, M Jones, T H LeJemtel.   

Abstract

BACKGROUND: Long-term beta-adrenergic blockade does not appear to be associated with drug-induced training in patients with congestive heart failure (CHF); whether exercise training can increase peak aerobic capacity in patients with CHF who are treated with beta-adrenergic blockers is currently unknown. METHODS AND
RESULTS: We studied 23 patients with CHF who were treated with carvedilol or propranolol in addition to ACE inhibitors, furosemide, and digoxin. Of the patients treated with carvedilol, 8 underwent exercise training and 8 remained sedentary. All 7 patients treated with propranolol underwent exercise training. Peak oxygen consumption (mL.kg-1.min-1) was serially measured in trained and sedentary patients. Peak reactive hyperemia (mL.min-1.100 mL-1) was determined in the calf and forearm immediately before and after 12 weeks of training. The peak oxygen consumption of trained patients treated with either carvedilol or propranolol increased from 12.9 +/- 1.4 to 16.0 +/- 1.6 (P < .001) and 12.4 +/- 1.0 to 15.7 +/- 0.9 (P < .001) mL.kg-1.min-1, respectively, whereas it did not change in the sedentary patients. Peak reactive hyperemia increased significantly in the calves but not the forearms of trained patients.
CONCLUSIONS: Long-term, nonselective beta-adrenergic blockade with carvedilol or propranolol does not prevent patients with CHF from deriving systemic and regional benefits from physical training.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9107160     DOI: 10.1161/01.cir.95.7.1764

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  11 in total

Review 1.  Clinical utility of exercise training in chronic systolic heart failure.

Authors:  Andrew J Stewart Coats
Journal:  Nat Rev Cardiol       Date:  2011-04-26       Impact factor: 32.419

Review 2.  Exercise testing with concurrent beta-blocker usage: is it useful? What do we learn?

Authors:  Eugene E Wolfel
Journal:  Curr Heart Fail Rep       Date:  2006-06

3.  The role of exercise therapy in the treatment of patients with systolic heart failure.

Authors:  Andrew Kao
Journal:  Curr Treat Options Cardiovasc Med       Date:  2006-08

Review 4.  Physical training as an adjunct therapy in patients with congestive heart failure: patient selection, training protocols, results, and future directions.

Authors:  R Hambrecht; S Gielen; G Schuler
Journal:  Curr Cardiol Rep       Date:  1999-05       Impact factor: 2.931

Review 5.  Muscle reflex control of sympathetic nerve activity in heart failure: the role of exercise conditioning.

Authors:  M H Khan; L I Sinoway
Journal:  Heart Fail Rev       Date:  2000-03       Impact factor: 4.214

Review 6.  Angiotensin II--nitric oxide interactions in the control of sympathetic outflow in heart failure.

Authors:  I H Zucker; J L Liu
Journal:  Heart Fail Rev       Date:  2000-03       Impact factor: 4.214

Review 7.  Marathoners or couch potatoes: what is the role of exercise in the management of heart failure?

Authors:  Eugene E Wolfel
Journal:  Curr Heart Fail Rep       Date:  2005-03

Review 8.  Regulation of central angiotensin type 1 receptors and sympathetic outflow in heart failure.

Authors:  Irving H Zucker; Harold D Schultz; Kaushik P Patel; Wei Wang; Lie Gao
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-08-28       Impact factor: 4.733

9.  Exercise training improves cardiac function and attenuates arrhythmia in CPVT mice.

Authors:  Efrat Kurtzwald-Josefson; Edith Hochhauser; Guy Katz; Eyal Porat; Jonathan G Seidman; Christine E Seidman; Yelena Chepurko; Asher Shainberg; Michael Eldar; Michael Arad
Journal:  J Appl Physiol (1985)       Date:  2012-10-04

Review 10.  Central adaptations to exercise training in patients with chronic heart failure.

Authors:  Alessandro Mezzani; Ugo Corrà; Pantaleo Giannuzzi
Journal:  Heart Fail Rev       Date:  2008-02       Impact factor: 4.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.